Marta Caamaño-Moreno

Marta Caamaño-Moreno

Auto-generated profile, based on publicly available information

Marta Caamaño-Moreno

Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
BSBerta Segura-Collar
Berta Segura-Collar
BCBlanca Cómitre-Mariano
Blanca Cómitre-Mariano
DLDenisse Alcivar López
Denisse Alcivar López
LMLucia Modejar-Ruescas
Lucia Modejar-Ruescas
MCMarta Caamaño-Moreno
Marta Caamaño-Moreno
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment. However, it is still not known why GBM is characterized by an immune-cold tumor microenvironment with reduced CD8+ T-cell infiltration when there is substantial myeloid cell infiltration and a substantial alteration of the blood-brain barrier. The aim of this study was to identify regulators of low CD8+ T-cell infiltration in GBM. Using transcriptomic screening, we found that tribbles homolog 2 (TRIB2) is a regulator of the immune-cold microenvironment characteristic of GBM. Further analysis of a cohort of 114 brain tumors with IHC, RNA sequencing, and qRT-PCR showed that TRIB2 inhibited the transcription of genes involved in antigen presentation by the tumor cells and those involved in T-cell recruitment by modulating the expression of methylation regulators, in particular DNA methyltransferase 1. Further, we observed 75% survival after TRIB2 inhibition in murine glioma models and showed transcriptomic reprogramming by decitabine of genes involved in the processes described above. In our patient-derived tumor fragments assay, we observed a consistent, generalized response to decitabine, suggesting that DNA methyltransferase 1 inhibition (DNMT1) could be a promising therapeutic strategy for GBM.

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
MCMarta Caamaño-Moreno
Marta Caamaño-Moreno
LMLucía Mondéjar-Ruescas
Lucía Mondéjar-Ruescas
SVSara Hiller Vallina
Sara Hiller Vallina
BSBerta Segura-Collar
Berta Segura-Collar
RGRicardo Gargini
Ricardo Gargini


2 July 2025
Verified
Other
Open access
PDF file
BSBerta Segura-Collar
Berta Segura-Collar
BCBlanca Cómitre-Mariano
Blanca Cómitre-Mariano
DLDenisse Alcivar López
Denisse Alcivar López
LMLucia Modejar-Ruescas
Lucia Modejar-Ruescas
MCMarta Caamaño-Moreno
Marta Caamaño-Moreno
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
Supplementary figure S5. DAC generated a significantly increased increase in antigen presentation and leukocyte recruitment gene signatures in PDTF assays.